Mirae Asset Global ETFs Holdings
VRDN icon

Mirae Asset Global ETFs Holdings’s Viridian Therapeutics VRDN Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$998K Buy
54,051
+5,856
+12% +$94.4K ﹤0.01% 1630
2026
Q1 		$932K Buy
48,195
+5,308
+12% +$158K ﹤0.01% 1558
2025
Q4 		$1.33M Buy
42,887
+7,025
+20% +$193K ﹤0.01% 1359
2025
Q3 		$774K Sell
35,862
-5,936
-14% -$107K ﹤0.01% 1641
2025
Q2 		$586K Sell
41,798
-7,478
-15% -$101K ﹤0.01% 1738
2025
Q1 		$669K Buy
49,276
+876
+2% +$14.9K ﹤0.01% 1707
2024
Q4 		$930K Buy
48,400
+13,990
+41% +$304K ﹤0.01% 1581
2024
Q3 		$783K Buy
34,410
+2,920
+9% +$47.7K ﹤0.01% 1676
2024
Q2 		$408K Buy
+31,490
New +$436K ﹤0.01% 1913

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's VRDN Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Viridian Therapeutics (VRDN) stake by 12% in Q2 2026, buying an estimated $94.4K and bringing the position to 54,051 shares worth $998K. The position accounts for ﹤0.01% of the portfolio, ranked #1630.

Mirae Asset Global ETFs Holdings first reported a position in VRDN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.33M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 54,051 shares of Viridian Therapeutics worth $998K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 5,856 Viridian Therapeutics shares in Q2 2026, an estimated $94.4K.
  • Viridian Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1630 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Viridian Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Viridian Therapeutics position peaked at $1.33M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.